MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology

LA JOLLA, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Good Manufacturing Practice (GMP)-based Master Virus Seed Stock (MVSS) production of its novel intranasal SARS-CoV-2 vaccine for COVID-19, using BC-PIV technology, has been initiated at Millipore Sigma BioReliance Services, a group company of Merck KGaA, Darmstadt, Germany.Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. commented, “We are pleased to begin production of MVSS, a key step in the production of vaccines, at Millipore Sigma BioReliance Services. We look forward to producing an effective intranasal COVID-19 vaccine and reporting additional development...

Continue reading

Martela Oyj: Managers’ transactions

Martela Oyj: Managers’ transactionsPerson subject to the notification requirementName: Vepsäläinen, AnniPosition: Member of the BoardIssuer: Martela OyjLEI: 743700M4EIEVD61PNN55Notification type: INITIAL NOTIFICATIONReference number: 743700M4EIEVD61PNN55_20201124082826_2Transaction date: 2020-11-19Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009900385Nature of the transaction: ACQUISITIONTransaction details(1): Volume: 2,000 Unit price: 2.55000 EURAggregated transactions(1): Volume: 2,000 Volume weighted average price: 2.55000 EURMartela PLCKalle LehtonenCFOtel +358 400 539 968Distribution:Nasdaq Helsinkiwww.martela.comOur strategic direction is defined by our mission “Better working” and our vision “People-centric workplaces”. Martela provides people centric workplaces where the users and their wellbeing are...

Continue reading

SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will participate in a Fireside Chat at the 3rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Wednesday, December 2, 2020 at 12:35 p.m. ET.A video webcast will be available on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying...

Continue reading

Etrion Presents at Fearnley Securites Annual Renewables Seminar 2020

GENEVA, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, announces that the Company’s Chief Executive Officer, Marco A. Northland, will be presenting at the Fearnley Securites Annual Renewables Seminar on Tuesday, November 24, 2020 at 2:10 pm Central European Time.The presentation will be live online and a copy of the material will be available on Etrion’s website www.etrion.com shortly afterwards.About EtrionEtrion Corporation is an independent power producer that develops, builds, owns and operates utility-scale solar power generation plants. The Company owns and operates 57 MWp of solar capacity and owns the 45 MWp Niigata project under construction, all in Japan. The Company is listed on the Toronto Stock Exchange in Canada...

Continue reading

Martela Oyj: Johdon liiketoimet

Martela Oyj: Johdon liiketoimetIlmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700M4EIEVD61PNN55_20201124082826_2Liiketoimen päivämäärä: 2020-11-19Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Instrumenttityyppi: OSAKEISIN: FI0009900385Liiketoimen luonne: HANKINTALiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 2 000 Yksikköhinta: 2,55000 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 2 000 Keskihinta: 2,55000 EURMartela OyjKalle LehtonenTalousjohtajapuh 0400 539 968Jakelu:Nasdaq Helsinkiwww.martela.fiMissiomme ”better working” ja visiomme ”people centric workplaces” määrittelevät strategisen suuntamme. Martela toimittaa käyttäjälähtöisiä työympäristöjä, joissa käyttäjät ja heidän hyvinvointi ovat keskiössä. Keskitymme  Pohjoismaihin, sillä yhteisen avoimen työkulttuuritaustamme ja tarpeidemme myötä Pohjoismaat ovat hybridien työympäristöjen...

Continue reading

Awilco Drilling PLC: Q3 2020 Presentation

Please find attached the Q3 2020 presentation to be held in the digital meeting today, 24 November 2020, at 12:00 UK time (13:00pm CET / 07:00 EST).To join the digital meeting, please click this link or copy and paste the following address into your browser: https://bit.ly/AWDR-Q3-2020Aberdeen, 24 November 2020For further information please contact:Jens Berge, CEOPhone: +44 1224 737900Cathrine Haavind, IR ManagerPhone: +47 93 42 84 64Email: ch@awilcodrilling.comThis information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. AttachmentAWDR Q3 2020 pres

Continue reading

Et robust finansielt resultat og fortsat strategisk fremgang i 2019/20 på trods af COVID-19

Nørresundby, den 24. november 2020Selskabsmeddelelse nr. 39/2020Årsrapport 2019/20(perioden 01.10.2019 – 30.09.2020)Regnskabsåret 2019/20 udviklede sig ganske anderledes end forventet. COVID-19 pandemien, og de modforanstaltninger, som er iværksat i hele verden mod pandemien, har resulteret i en global økonomisk usikkerhed, som også har påvirket RTX’s markeder. RTX’s forretningsmodel er dog fortsat stærk, og med en tæt omkostningsstyring har RTX formået at slutte året med en indtjening indenfor de oprindelige forventninger på trods af en omsætning, som blev lavere end oprindeligt forventet.HOVEDPUNKTER I ÅRSRAPPORTEN FOR 2019/20RTX indfriede de forventninger til indtjeningen, som blev annonceret i starten af året på trods af, at omsætningen blev lavere end oprindeligt forventet på grund af COVID-19 og den efterfølgende globale økonomiske...

Continue reading

Útboð á grænum skuldabréfum 1. desember

Þriðjudaginn 1. desember 2020 verða boðin til sölu í lokuðu útboði skuldabréf í grænum skuldabréfaflokkum Orkuveitu Reykjavíkur, OR020934 GB og OR180255 GB.OR020934 GB ber fasta verðtryggða vexti og greiðir jafnar greiðslur á sex mánaða fresti með lokagjalddaga 2.september 2034.OR0180255 GB ber fasta verðtryggða vexti og greiðir jafnar greiðslur á sex mánaða fresti með lokagjalddaga 18. febrúar 2055.Áður hafa verið gefin út bréf í flokkunum að nafnvirði 7.145 m.kr. í OR020934 GB og að nafnvirði 21.981 m.kr. í OR180255 GB.Útgáfa skuldabréfaflokkanna er í samræmi við áður samþykkta lántökuheimild Orkuveitu Reykjavíkur fyrir árið 2020.Fossar markaðir hafa umsjón með útgáfu og sölu skuldabréfanna.Nánari upplýsingar:Ingvar StefánssonFramkvæmdastjóri Fjármála ORSími: 516-6100Netfang: ingvar.stefansson@or.isMatei ManolescuMarkaðir, Fossar markaðirSími:...

Continue reading

Green Bond Offering on December 1st

Reykjavik Energy (OR; Orkuveita Reykjavikur) will conduct a closed auction of inflation linked green bonds in the series OR020934 GB and OR180255 GB on December 1st, 2020.OR020934 GB pays a fixed real-interest rate, has a semiannual annuity amortization schedule and a final maturity on September 2nd 2034.OR0180255 GB pays a fixed real-interest rate, has a semiannual annuity amortization schedule and a final maturity on February 18th 2055.Previously issued bonds in the series amount to a nominal value of ISK 7,145m in OR020934 GB and ISK 21,981m in OR180255 GB.The bond offering confirms with approved financing in the form of loans, bonds or bills of Reykjavík Energy for the year 2020.Fossar Markets will manage the auction on behalf of OR and will handle investor relations.Further information:Ingvar StefánssonCFO, Reykjavik Energy+354 516-6100ingvar.stefansson@or.isMatei...

Continue reading